These tests analyze tumor DNA and RNA to identify key genetic alterations, such as mutations in the IDH1 and IDH2 genes, MGMT promoter methylation, and EGFR amplification, which are pivotal in glioblastoma classification and prognosis. This evidence concerns the gene IDH1 and glioblastoma.